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Objectives
To assess the efficacy and tolerability of the dual epidermal
growth factor receptor/vascular endothelial growth factor
receptor inhibitor, vandetanib, in combination with
carboplatin and gemcitabine in the first-line treatment of
patients with advanced transitional cell carcinoma urothelial
cancer (UC) who were unsuitable for cisplatin.
Patients and methods
From 2011 to 2014, 82 patients were randomised from 16
hospitals across the UK into the TOUCAN double-blind,
placebo-controlled randomised Phase II trial, receiving six
21-day cycles of intravenous carboplatin (target area under
the concentration versus time curve 4.5, day 1) and
gemcitabine (1000 mg/m2 days 1 and 8) combined with
either oral vandetanib 100 mg or placebo (once daily).
Progression-free survival (PFS; primary endpoint), adverse
events, tolerability and feasibility of use, objective response
rate and overall survival (OS) were evaluated. Intention-to-
treat and per-protocol analyses were used to analyse the
primary endpoint.
Results
The 82 patients were randomised 1:1 to vandetanib (n = 40)
or placebo (n = 42), and 25 patients (30%) completed six
cycles of all allocated treatment. Toxicity Grade ≥3 was
experienced in 80% (n = 32) and 76% (n = 32) of patients in
the vandetanib and placebo arms, respectively. The median
PFS was 6.8 and 8.8 months for the vandetanib and placebo
arms, respectively (hazard ratio [HR] 1.07, 95% confidence
interval [CI] 0.65–1.76; P = 0.71); the median OS was 10.8 vs
13.8 months (HR 1.41, 95% CI 0.79–2.52; P = 0.88); and
radiological response rates were 50% and 55%.
Conclusion
There is no evidence that vandetanib improves clinical
outcome in this setting. Our present data do not support its
adoption as the regimen of choice for first-line treatment in
patients with UC who were unfit for cisplatin.
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Introduction
There are ~10 000 patients newly diagnosed with urothelial
cancer (UC) in the UK [1] and 118 000 in Europe [2] per
annum. Around 38% die within 1 year of diagnosis. The
majority of UC deaths are caused by locally advanced or
metastatic invasive bladder cancer. Advanced UC is a
chemosensitive disease with response rates to cisplatin-
containing regimens in previously untreated patients of
~55% and with a median overall survival (OS) in the region
of 14 months [3,4]. However, cisplatin-based chemotherapy
is not suitable for ~40% of patients [5], due to reasons such
as insufficient renal function, performance status or
comorbidity. Much of the focus of clinical trials has been
on improving outcomes in the cisplatin-fit population, but
there is also a need to improve outcomes in the sizable
minority of patients currently treated with non-cisplatin
containing regimens.
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For many of these patients, the standard of care is a
combination gemcitabine plus carboplatin (GC)
chemotherapy, giving a median progression-free survival
(PFS) of between 4.8 and 5.3 months [6-9]. UC frequently
expresses a variety of growth factor receptors, including
epidermal growth factor receptors (EGFRs) and vascular
endothelial growth factor receptors (VEGFRs) [10-12]. Over-
expression of VEGF and its receptors in UC was associated
with poor prognosis [13,14], suggesting a role for VEGF/
VEGFRs in pathogenesis and potential clinical utility for
molecularly targeted agents directed against these cell-surface
receptors.
Vandetanib (ZD6474; Caprelsa) is an oral tyrosine kinase
inhibitor selective for VEGFR-1, VEGFR-2, VEGFR-3, and
EGFR. Preclinical data have shown that vandetanib induced
cell death in vitro at clinically meaningful concentrations in
several UC cell lines, and that this effect was synergistic with
platinum-containing chemotherapy agents [15]. In vivo,
pharmacological inhibition of EGFR or VEGFR had anti-
tumoral effects in carcinogen-induced and orthotopic models
of bladder cancer, respectively [16,17]. Vandetanib has shown
efficacy as a single agent in clinical trials for medullary
thyroid cancer [18], and in combination with docetaxel in the
second-line treatment of locally advanced or metastatic non-
small cell lung cancer [19].
Our hypothesis was that co-targeting both EGFRs and
VEGFRs may improve survival outcomes in patients with
advanced UC who are not suitable to receive cisplatin as first-
line treatment. The primary goal of the TOUCAN trial was to
establish whether vandetanib combined with GC
chemotherapy is safe and gives sufficient activity to warrant a
future Phase III trial in this patient group.
Patients and methods
Study design
TOUCAN was a double-blind, parallel group, randomised
screening Phase II trial approved by a UK multicentre
research ethics committee (Ref:09/S0703/98) and the UK
Medicine and Health care products Regulatory Agency
(MHRA) [ClinicalTrials.gov Identifier: NCT01191892 and
International Standard Randomised Controlled Trial Number
(ISRCTN) 68146831]. The TOUCAN trial was funded by the
AstraZeneca and the UK National Institute for Health
Research (NIHR) Clinical Research Network (CRN):Cancer –
Combinations Alliance, Cancer Research UK (CRUKE/09/
024), and CRUK core funding to the Centre for Trials
Research, Cardiff University . This was an academically
sponsored clinical trial sponsored by Cardiff University.
Patients were eligible if they were aged ≥18 years; had
histologically confirmed UC with TCC (pure or mixed
histology); had radiologically measurable, locally advanced
and/or metastatic disease [Response Evaluation Criteria In
Solid Tumors (RECIST), version 1.1]; were not amenable to
curative treatment with surgery or radiotherapy; and were
not suitable for cisplatin. Unsuitability for cisplatin was
defined as one or more of the following: (i) creatinine
clearance <60 mL/min; (ii) Eastern Cooperative Oncology
Group Performance Status (ECOG PS) =2 (N.B. patients
are excluded if ECOG PS was >=3) ; (iii) clinically
significant ischaemic heart disease; (iv) prior intolerance of
cisplatin; (v) age >75 years; (vi) any other factor, which, in
the opinion of the investigator indicated that cisplatin was
not suitable. Patients were also ineligible for the trial if
their creatinine clearance was <30 mL/min. All patients
provided written informed consent.
The patients were randomly assigned (1:1) either to
vandetanib or placebo in addition to GC with stratification by
institution, ECOG PS (0–1 and 2) and renal function
(creatinine clearance <60 vs ≥60 mL/min, calculated using the
Cockcroft and Gault formula) using a central interactive web
response system.
All patients received up to six 21-day cycles of carboplatin
[target area under the concentration versus time curve
(target AUC) 4.5] by intravenous infusion over 30–60 min
on day 1 and gemcitabine (1000 mg/m2) by intravenous
infusion over 30 min, days 1 and 8, in combination with
either vandetanib 100 mg or placebo once daily. The
carboplatin dose was calculated using the Calvert formula
{carboplatin dose (mg) = AUC 9 [GFR (mL/min) + 25]}.
The corrected QT interval and laboratory safety parameters
were measured every 21 days throughout the treatment
phase.
Clinical and radiological response assessments were
performed at weeks 9, 18, 26, 39 and 52 after the
commencement of treatment, with radiological response
assessed by comparison with baseline data, according to
RECIST, version 1.1.
Endpoints
The primary endpoint was PFS, defined as the time
from randomisation to disease progression and/or death.
Those still alive and progression free were censored at the
date last seen. Secondary endpoints included: safety,
assessed via real-time serious adverse event (AE) reporting
and at patients visits using the Common Terminology
Criteria for Adverse Events (CTCAE), version 4.0;
tolerability and feasibility of use of treatment, which was
assessed by calculating the number of treatment
reductions, delays and treatment withdrawals; objective
response, which was derived from radiological assessments
and; OS, defined as the time from randomisation to death
from any cause, censoring for those still alive at time last
seen.
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Statistical analysis
This was a placebo-controlled, randomised screening Phase II
trial. The median PFS in patients with advanced UC not
suitable for cisplatin was estimated to be ~5.3 months with
chemotherapy. The sample size was calculated assuming 24-
month recruitment, with 80% power and a one-sided a (type I
error) of 0.2. Allowing a drop-out rate of 5%, 82 participants
and 62 (PFS) events were required to demonstrate a hazard
ratio (HR) of 0.65, based on the log-rank test. The data were
analysed after 65 events were observed. A Phase III
confirmatory trial was to be planned if there was statistical
significance at the 10% level. In the event of statistical
significance between 10.1% and 20%, a confirmatory trial was
planned only if secondary endpoints indicated benefit.
At the end of the trial, analyses were performed on both
intention-to-treat (ITT) and planned-per-protocol analysis
(PPA) basis. The PPA excluded patients found to be ineligible
or who did not start their trial medication during cycle 1.
Kaplan–Meier curves of PFS and OS were plotted and these
were used to calculate the median PFS and OS for each arm.
The Mantel–Cox version of the log-rank test (unadjusted)
was used to assess the effect of vandetanib on PFS and OS. In
addition, a planned adjusted analysis for the primary
endpoint of PFS using a Cox proportional hazards model,
including the stratification factors used in the randomisation,
was performed (i.e., ECOG PS and renal function, with
institution included in the model as a shared frailty). The
secondary endpoints were presented as the proportion (and
95% CI) of patients in each treatment arm with: (i) an
objective disease response (based on RECIST v1.1); (ii) Grade
≥3 toxicity; and (iii) a treatment reduction, delay and
treatment withdrawal. No subgroup analyses were performed.
There were no pre-defined early stopping guidelines.
An independent safety committee reviewed the trial
throughout; including formal safety reviews after the first 10
and 20 patients in each arm had been recruited.
Results
Baseline patient and tumour characteristics
The 82 patients were randomised from 16 hospitals across the
UK, between April 2011 and December 2014. A Consolidated
Standards of Reporting Trials (CONSORT) diagram is shown
in Fig. 1. Baseline patient and tumour characteristics were
similar in the two treatment arms and are presented in
Table 1.
Treatment tolerability and feasibility of use
In all, 13 (33%) of the 40 participants assigned to receive
vandetanib and 25 (60%) of the 42 assigned to placebo
received all six cycles of GC. The median (interquartile range
[IQR]) numbers of cycles received were 5 (3.5–6) and 6 (4–
6), in the vandetanib and placebo arms, respectively. Patients
received a median (IQR) of 88 (46–116) days of vandetanib
and 105 (63–126) days of placebo. Eight (20%) of the 40
participants in the vandetanib arm received all six cycles of
vandetanib; 22 (55%) failed to do so because of toxicity, three
(8%) because of progression, three (8%) due to patient choice,
two (5%) due to death, and two (5%) for unknown reasons.
In all, 17 (41%) of the 42 patients in the placebo arm
received all six cycles of placebo; 14 (33%) did not do so due
to toxicity, seven (17%) due to disease progression, one (2%)
by patient choice, one (2%) due to death, and two (5%) for
unknown reasons.
Safety
Similar rates of treatment-emergent AEs were seen in the two
arms, with Grade 3–4 toxicities seen in 80% of patients in the
vandetanib arm and 76% in the placebo arm. The commonly
occurring toxicities are summarised in Table 2.
Efficacy
At the time of final analysis, a total of 65 patients (79%) had
progressed or died. Comparison of PFS between the two
treatment arms using ITT gave an unadjusted HR of
1.07 (95% CI 0.65–1.76; one-sided P = 0.71; Fig. 2A).
Corresponding adjusted analysis gave an HR of 1.04 (95% CI
0.63–1.71). The absolute difference in 1-year PFS was 1.9%
(12.9% in the vandetanib arm and 14.7% in the placebo arm),
95% CI 11.3% to 13.9%. The median PFS for the
vandetanib arm was 6.8 months (95% CI 4.6–8.5) and for the
placebo arm was 8.8 months (95% CI 5.7–9.0). An
unadjusted analysis using PPA gave a similar result with a
HR of 1.00 (95% CI 0.59–1.70).
In all, 32 patients (80%) in the vandetanib arm and 38 (90%)
in the placebo arm were evaluable for radiological response.
On an ITT basis, responses (complete response + partial
response) were seen in 20 of 40 patients (50%) in the
vandetanib arm and 23 of 42 (55%) in the placebo arm. The
change in size of measurable lesions at first protocol-
mandated response assessment (week 9 after commencement
of treatment; 64 evaluable patients) is presented as a waterfall
plot in Fig. 3.
A total of 48 patients (58%) had died by the time of analysis:
42 deaths were disease related, two were treatment related,
and four due to other reasons. The median OS for the
vandetanib arm was 10.8 months (95% CI 8.0–13.0) and for
the placebo arm was 13.8 months (95% CI 11.1–16.6).
Comparison of OS gave an unadjusted HR of 1.41 (95% CI
0.79– 2.52; one-sided P = 0.9), using an ITT analysis, which
represents a 41% increase in risk of death after the addition
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of vandetanib (Fig. 2B). There was a corresponding absolute
reduction of 10.6% in the 1-year OS in the vandetanib arm
(54.4% in the vandetanib arm vs 65.0% in the placebo arm)
(95% CI 31.2–6.0%).
Discussion
The goal of this trial was to assess the safety and efficacy of
vandetanib in combination with GC chemotherapy. Based on
this trial, although this combination was found to be safe,
there was no evidence that this combination improved
clinical outcomes in this cohort of patients with advanced UC
who were unsuitable for cisplatin. These data are consistent
with a previous report that vandetanib does not improve
efficacy when combined with docetaxel in patients receiving
second-line treatment of advanced UC [20]. Our present
results are in contrast to the small benefits seen with
vandetanib in combination with docetaxel in non-small cell
lung cancer [19] and with a recently reported randomised
Phase III trial using another anti-VEGFR agent, ramucirumab
(a fully human anti-VEGFR2 monoclonal antibody), which
demonstrated improved PFS and response rates in
combination with docetaxel for patients with UC in the
second-line setting [21]. However, the data presented in the
Screened (n=212) 
Enrolled (n=82) 
Allocated Vandetanib (n=40) Allocated Placebo (n=42) 
Included ITT analysis (n=40) Included ITT analysis (n= 42) 
Included in PP analysis (n=33) Included PP analysis (n= 37) 
Excluded from analysis because Excluded from analysis because 
• 
• 
Not eligible (n=6) • Not eligible (n=4) 
Not started trial medication 
cycle 1 (n=1) 
• Not started trial medication in 
cycle 1 (n=1) 
Completed 6 cycles of Vandetanib 
(n= 8) 
Completed 6 cycles of placebo 
(n=17) 
Failure due to Failure due to 
Toxicity (n=22) Toxicity (n=14) • 
Progression (n=3) 
• 
Progression (n=7) • 
• Patient choice (n=3) 
• 
Patient choice (n=1) 
• Death (n=2) 
• 
Death (n=1) 
• Other reasons (n=2) 
• 
• Other reasons (n=2) 
Fig. 1 CONSORT flow diagram of trial participants.
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present study are consistent with other trials exploring the
efficacy of drugs targeting the VEGFR pathways in UC [22],
with most agents tested having been found to have
insufficient activity to take to Phase III. Recent results of a
randomised Phase III trial of gemcitabine plus cisplatin with
or without bevacizumab in the first-line setting have shown
an improvement in PFS with the addition of bevacizumab,
but no improvement in the primary endpoint of OS
(ClinicalTrials.gov Identifier: NCT00942331; www.clinicaltria
ls.gov) [23]. Similarly, EGFR-targeted therapies have shown
insufficient activity in both biomarker-selected and -
unselected patients with UC. Notably, a Phase III trial of the
dual EGFR inhibitor, lapatinib (LaMB), in patients selected
for EGFR and/or human epidermal growth factor receptor 2
(HER2) expression, failed to show activity in advanced UC
following first-line chemotherapy [24].
One explanation for the lack of efficacy of vandetanib in the
present trial might have been failure to select patients
appropriately. Predictive markers for VEGF-targeted therapies
have, to date, been elusive in other disease and valid
predictive markers for EGFR-targeted therapies are not
sufficiently prevalent in UC [25].
Despite the failure to demonstrate incremental benefit from
vandetanib, the overall outcomes for patients in the present
trial were better than expected. Notably, in both arms of the
present study the median PFS (6.8 vs 8.8 months) and OS
(10.8 vs 13.8 months) were better than seen in a previous
Phase III trial of GC chemotherapy in a similar group of
patients (PFS 5.8 months and OS 9.3 months) [6]. This may
reflect patient selection, as patients needed to be considered
suitable for combination treatment by investigators or could
be due to the use of a wider definition of ‘unsuitable for
cisplatin’. We cannot be certain as to the reasons for the
apparent trend towards poorer survival amongst those
receiving vandetanib, but it could have been due to reduced
exposure to chemotherapy seen in this arm. In addition, there
were some imbalances in baseline characteristics between the
arms.
After many years in which various combinations of small-
molecule cytotoxic drugs and/or molecularly targeted drugs
have failed to achieve substantial improvements in survival
outcomes in advanced UC, significant interest has recently
been generated in the use of immunotherapies, including a
report of improved survival with the anti-programmed
cell death-1 (PD-1) monoclonal antibody, pembrolizumab, as
second-line therapy for metastatic UC [26]. Our response rate
(50%) and OS data (median OS 10.8 months) in the
vandetanib arm are not dissimilar to those seen in a trial of
pembrolizumab in the same setting (first-line treatment of
patients with metastatic UC unsuitable for cisplatin), which
reported an objective response rate (ORR) of 24% and a
median OS of 11.5 months [27] and with a single-arm trial of
the anti-PD-L1 monoclonal antibody, atezolizumab, which
demonstrated an ORR of 23% and a median OS of
15.9 months [28]. Several Phase III trials comparing GC with
immunotherapy in the population unsuitable for cisplatin are
currently unreported (ClinicalTrials.gov Identifier:
NCT02516241; NCT02853305; NCT02807636; www.clinica
ltrials.gov).
In conclusion, there is no evidence that the addition of
vandetanib to GC chemotherapy improves clinical outcomes.
Our present findings do not support a Phase III study or its
use as first-line treatment in patients with UC who are unfit
for cisplatin.
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Table 1 Patients’ characteristics.
Characteristic Vandetanib Placebo
Total number of patients enrolled 40 42
Age, years, median (IQR) 73.5 (66–77) 73.5 (67–79)
Reason not suitable for cisplatin, n (%)
Renal function GFR <60 mL/min 27 (69.2) 29 (69.1)
ECOG PS 2 10 (26.3) 10 (23.8)
Ischaemic heart disease 4 (10.3) 6 (14.3)
Prior intolerance to cisplatin 0 (0.0) 5 (11.9)
Age >75 years 13 (34.2) 23 (54.8)
Other 13 (34.2) 17 (40.5)
Sex, n (%)
Male 32 (80.0) 35 (83.3)
Female 8 (20.0) 7 (16.7)
Location of primary disease, n (%)
Bladder 28 (70.0) 34 (81.0)
Other 12 (30.0) 8 (19.1)
Stage, n (%)
T4, T4a, T4b 9 (22.5) 5 (12.2)
N1, N2, N3 28 (70.0) 25 (59.5)
M1 22 (55.0) 18 (42.9)
Previous neoadjuvant chemotherapy, n (%)
Yes 4 (10) 4 (9.5)
Metastasis, n (%)
Lung 13 (32.5) 8 (19.0)
Liver 2 (5.0) 7 (16.7)
Nodes 25 (62.5) 25 (59.5)
Bone 2 (5.0) 4 (9.5)
Other 6 (15.0) 7 (16.7)
None 7 (17.5) 9 (21.4)
Bajorin Risk Group, n (%)
0 (no visceral metastases and ECOG PS <2) 16 (41.0) 21 (50.0)
1 (visceral metastases or ECOG PS ≥2) 22 (56.4) 19 (45.2)
2 (visceral metastases and ECOG PS ≥2) 1 (2.6) 2 (4.8)
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Table 2 Treatment-emergent AEs.
Vandetanib (N = 40) Placebo (N = 42)
Any, n (%) ≥3, n (%) Any, n (%) ≥3, n (%)
36 (90) 32 (80) 41 (98) 32 (76)
Blood and lymphatic system disorders
Anaemia 26 (65) 6 (15) 25 (60) 8 (19)
Gastrointestinal disorders
Abdominal pain 5 (13) 1 (3) 9 (21) 0 (0)
Constipation 6 (15) 0 (0) 11 (26) 0 (0)
Diarrhoea 15 (38) 1 (3) 10 (24) 0 (0)
Dyspepsia 4 (10) 0 (0) 2 (5) 0 (0)
Mucositis (oral) 7 (18) 0 (0) 7 (17) 0 (0)
Nausea 14 (35) 2 (5) 12 (29) 1 (2)
Vomiting 7 (18) 2 (5) 13 (31) 0 (0)
General disorders and administration site conditions
Oedema of the limbs 3 (8) 0 (0) 7 (17) 0 (0)
Fatigue 24 (60) 1 (3) 30 (71) 1 (2)
Fever 3 (8) 1 (3) 5 (12) 2 (5)
Pain 14 (35) 1 (3) 15 (36) 3 (7)
Infections and infestations
Infections 0 (0) 0 (0) 4 (10) 1 (2)
Lung 5 (13) 1 (3) 3 (7) 0 (0)
Investigations
ALP 9 (23) 0 (0) 9 (21) 1 (2)
Neutrophil count decreased 15 (38) 12 (30) 15 (36) 8 (19)
ALT 13 (33) 0 (0) 12 (29) 2 (5)
AST 6 (15) 0 (0) 5 (12) 0 (0)
Creatinine increased 6 (15) 0 (0) 7 (17) 1 (2)
Lymphocyte count 18 (45) 2 (5) 12 (29) 2 (5)
Platelet count decreased 23 (58) 19 (48) 19 (45) 12 (29)
Weight 5 (13) 0 (0) 6 (14) 0 (0)
WBC 19 (48) 7 (18) 21 (50) 6 (14)
Metabolism and nutrition disorders
Anorexia 11 (28) 0 (0) 8 (19) 0 (0)
Hyperglycaemia 2 (5) 0 (0) 4 (10) 1 (2)
Hyperkalaemia 2 (5) 1 (3) 2 (5) 0 (0)
Hypomagnesaemia 8 (20) 0 (0) 8 (19) 0 (0)
Hypophosphataemia 9 (23) 1 (3) 3 (7) 1 (2)
Hypokalaemia 7 (18) 1 (3) 2 (5) 0 (0)
Musculoskeletal and connective tissue disorders
Back pain 5 (13) 0 (0) 2 (5) 1 (2)
Myalgia 4 (10) 0 (0) 0 (0) 0 (0)
Nervous system disorders
Dizziness 4 (10) 0 (0) 5 (12) 0 (0)
Insomnia 6 (15) 0 (0) 3 (7) 0 (0)
Renal and urinary disorders
Acute kidney injury 4 (10) 3 (8) 2 (5) 1 (2)
Proteinuria 6 (15) 2 (5) 4 (10) 0 (0)
Haematuria 10 (25) 3 (8) 8 (19) 2 (5)
UTI 6 (15) 5 (13) 4 (10) 1 (2)
Respiratory, thoracic and mediastinal disorders
Cough 10 (25) 0 (0) 4 (10) 0 (0)
Dyspnoea 11 (28) 0 (0) 8 (19) 0 (0)
Epistaxis 4 (10) 1 (3) 2 (5) 0 (0)
Respiratory infection 4 (10) 2 (5) 1 (2) 1 (2)
Skin and subcutaneous tissue disorders
Alopecia 3 (8) 0 (0) 5 (12) 0 (0)
PPE 7 (18) 0 (0) 1 (2) 0 (0)
Photosensitivity 6 (15) 3 (8) 0 (0) 0 (0)
Pruritus 3 (8) 2 (5) 4 (10) 0 (0)
Rash 19 (48) 5 (13) 11 (26) 0 (0)
Skin infection 2 (5) 2 (5) 4 (10) 3 (7)
Vascular disorders
Hypertension 6 (15) 5 (13) 6 (14) 1 (2)
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PPE, palmar-plantar erythrodysesthesia syndrome; WBC, white blood cell count. All
AEs with ≥10% any grade incidence in either arm from initiation of study treatment.
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